Research programme: cancer therapeutics - D-Pharm

Drug Profile

Research programme: cancer therapeutics - D-Pharm

Alternative Names: DP-266; DP-388; DP-411

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator D-Pharm
  • Class Lipids
  • Mechanism of Action G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Pancreatic cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Pancreatic-cancer in Israel
  • 08 Sep 2010 This programme is still in active development
  • 06 Mar 2008 Preclinical development of DP 388 is ongoing for pancreatic cancer in Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top